DDX39A and hepatocellular carcinoma: We found β-catenin overexpression couldnot promote DDX39 expression (data not show), DDX39 was an upstream molecule of Wnt/β-catenin pathway, and was a good target for HCC therapy, how DDX39 activates Wnt/β-catenin still is to be explored.